CRISPR Therapeutics AG (NASDAQ:CRSP) saw an upside of 1.93% to close Tuesday at $102.59 after adding $1.94 on the day. The 5-day average trading volume is 1,871,440 shares of the company’s common stock. It has gained $105.59 in the past week. An average of 1,247,830 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,117,966.
CRSP’s 1-month performance is -13.06% or -$18.15 on its low of $96.55 reached on 10/08/21. The company’s shares have touched a 52-week low of $84.38 and high of $220.20, with the stock’s rally to the 52-week high happening on 01/15/21. YTD, CRSP has lost -33.00% or -$50.52. However, the current price is down -53.41%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Aug 06, 68 days have gone by since the last insider trading activity for CRISPR Therapeutics AG (CRSP). TOMSICEK MICHAEL JOHN (Chief Financial Officer) most recently sold 25,000 shares at $138.52 per share on Aug 06. This transaction cost the insider $3,462,926. Chief Executive Officer, Kulkarni Samarth, sold 28,500 shares at a price of $128.98 on Aug 05. Then, on Aug 04, Chief Executive Officer Kulkarni Samarth sold 1,500 shares at a price of $125.02 per share. This transaction amounted to $187,530.
The company’s PE ratio for the last five years has touched a high of 218.78 and a low of 19.38. CRSP stock has a beta of 2.23. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.05 while the price-to-book (PB) in the most recent quarter is 2.99, with the price to cash flow ratio at 16.25.
CRISPR Therapeutics AG’s quick ratio for the period ended June 29 was 26.20, with the current ratio over the same period at 26.20 meaning that CRSP stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -48018.22% while for the period ending June 29; CRISPR Therapeutics AG’s operating margin was 49.70%. The firm’s gross profit as reported stood at $355.15 million against revenue of $0.72 million.
For the quarterly period ending June 29 this year, CRISPR Therapeutics AG’s cash and short-term investments amounted to $942.8 million against total debt of $191.2 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 100.0% to $900.7 million, while revenue of $0.54 million was 99.94% off the previous quarter. Analysts expected CRSP to announce $3.52 per share in earnings in its latest quarter, but it posted $9.44, representing a 168.20% surprise. EBITDA for the quarter stood at more than $766.27 million. CRSP stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 295.72 million, with total debt at $191.2 million. Shareholders hold equity totaling $76.2 million
Let’s look briefly at CRISPR Therapeutics AG (CRSP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 36.18% to suggest the stock is trending Neutral, with historical volatility in this time period at 50.77%.
The stock’s 5-day moving average is $101.37, reflecting a +0.10% or $0.10 change from its current price. CRSP is currently trading -11.79% above its 20-day SMA, -12.80% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -16.14% and -39.12% respectively.
Stochastic %K and %D was 15.85% and 13.84% and the average true range (ATR) pointed at 4.73. The RSI (14) points at 36.50%, while the 14-day stochastic is at 23.50% with the period’s ATR at 4.89. The stock’s 9-day MACD Oscillator is pointing at -3.26 and -7.40 on the 14-day charts.
In the most recent analyst report for CRISPR Therapeutics AG (NASDAQ: CRSP), Citigroup upgraded it to a Neutral rating. They previously had a Sell rating on the stock. Analysts offering their rating for CRSP stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate CRSP as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 13 have offered a “buy” rating.
What is CRSP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $117.00 and a high of $220.00, with their median price target at $165.00. Looking at these predictions, the average price target given by analysts is for CRISPR Therapeutics AG (CRSP) stock is $163.22.